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BACKGROUND: Although a weekly injection of 17-hydroxyprogestone eligible for 17-hydroxyprogesterone caproate eligible after medical record
caproate is recommended for preventing recurrent preterm birth, clinical
experience in North Carolina suggested that many eligible patients were
not receiving the intervention.
OBJECTIVE: Our study sought to assess how well practices
delivering at 2 major hospitals were doing in providing access to 17-
hydroxyprogesterone caproate treatment for eligible patients.
STUDY DESIGN: This retrospective cohort analysis studied all
deliveries occurring between January 1, 2012, and December 31, 2013,
at 2 large hospitals in North Carolina. Women were included if they had
a singleton pregnancy and history of a prior spontaneous preterm birth.
We extracted demographic, payer, and medical information on each
pregnancy, including whether women had been offered, accepted, and
received 17-hydroxyprogesterone caproate. Our outcome of 17-
hydroxyprogesterone caproate coverage was defined as documentation
of 1 injection of the drug.
RESULTS: Over the 2-year study period, 1216 women with history of a
prior preterm birth delivered at the 2 study hospitals, of which 627 werereview. Only 296 of the 627 eligible women (47%; 95% confidence
interval, 43e51%) received1 dose of the drug. In multivariable analysis,
hospital of delivery, later presentation for prenatal care, fewer prenatal
visits, later gestation of prior preterm birth, and having had a term delivery
immediately before the index pregnancy were all associated with failed
coverage. Among those women who were “covered,” the median number
of 17-hydroxyprogesterone caproate injections was 9 (interquartile range,
4e15), with 84 of 296 charts (28%) not having complete information on
the number of doses.
CONCLUSION: Even under our liberal definition of coverage, less than
half of eligible women received 17-hydroxyprogesterone caproate in this
sample. Low overall use suggests that there is opportunity for improve-
ment. Quality improvement strategies, including population-based mea-
surement of 17-hydroxyprogesterone caproate coverage, are needed to
fully implement this evidence-based intervention to decrease preterm birth.
Key words: implementation, prematurity, prevention, 17OHP-Cach year in the United States, nearlyE half a million infants are born
before 37 weeks gestation.1,2 In 2006, the
US preterm birth (PTB) rate reached a
record high of 12.8%.3 Since that time, it
has declined significantly to 11.32% in
2014,4 with the reductions thought to be
due to changes in elective deliveries
before 37 weeks.5-8 The number of early
preterm term births (<34 weeks) has not
seen significant improvement in the past
20 years, and it is these infants who
experience the highest rates of morbidity
and mortality.3,9
Ambitious goals have been adopted
by the Association of State andTerritorial Health Officials (ASTHO)10
and the March of Dimes11 for reducing
the disease burden caused by prematu-
rity. Central to these goals is a reduction
in the national PTB rate to 8.1% by 2020.
North Carolina, which has a preterm
birth rate of 9.7%, received a grade “C”
on its 2015 March of Dimes report card,
which refers to states with a preterm
birth rate between 9.3% and 10.3%.10 A
national target of 8.1% can be achieved
only through a systematic, multifaceted,
and coordinated effort. Although there
has been reasonable recent progressmade
toward mitigating some PTB risk factors
(smoking in pregnancy, elective late
preterm births),8 other areas still need
attention. These include the complexity
of addressing racial/ethnic inequalities
in perinatal care12,13 and increasing
coverage of known effective interventions
such as use of 17-hydroxyprogesterone
caproate (17OHP-C).
A history of a prior PTB is among
the most important risk factors for
spontaneous PTB in a subsequentpregnancy.14,15 Thus, women with a
history of PTB have been the focus of
interventions. In 2003, Meis and col-
leagues published the results of a multi-
center randomized trial showing that,
among women with singleton gestations
and history of a prior spontaneous PTB,
a weekly intramuscular injection of
17OHP-C (starting between 16 and 20
weeks and administered through de-
livery or 36 weeks’ gestation) reduced
the risk of recurrent PTB by 34%.16
Numerous professional organizations
in the United States, including the Soci-
ety for MaternaleFetal Medicine, the
American College of Obstetricians and
Gynecologists (ACOG), and the Amer-
ican Association of Midwives, have
endorsed the use of 17OHP-C treatment
in eligible women.17-19 The most recent
2012 ACOG Practice Bulletin on
preterm birth recommends tracking
the “percentage of women with a prior
spontaneous preterm birth who are
offered progesterone supplementation”
as a way to monitor implementation of
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A cohort of women potentially eligible to receive 17OHP-C prophylaxis and delivering at 2 North
Carolina Hospitals between January 1, 2012, and December 31, 2013.
IUFD, intrauterine fetal demise; PTB, preterm birth; 17P, 17OHP-C.
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specify how to carry out such moni-
toring, which populations to evaluate, or
appropriate data sources.
North Carolina has had a strong,
statewide 17OHP-C initiative for almost
9 years, and the UNC Center for
Maternal and Infant Health has dissem-
inated guidelines for the use of
17OHP-C based on the ACOG/SMFM
eligibility criteria on the Center’s website
(www.mombaby.org). However, there
are no coordinated efforts to monitorstatewide coverage of the intervention.
In an effort to characterize 17OHP-Cuse
in NC, we sought to assess what per-
centage of eligible women had received
at 17OHP-C at 2 major hospitals.
Material and Methods
We conducted a retrospective review
of all deliveries 20 weeks and above
occurring between January 1, 2012, and
December 31, 2013, at the University of
North Carolina (UNC) Women’s Hos-
pital (Chapel Hill, NC) and at MissionHospital (Asheville, NC). Both facilities
have perinatal databases that can be
queried for basic indicators, such as
parity, gestational age, and birth history.
We used these databases as a first pass
through the study population to identify
womenwhosemedical records should be
further evaluated, specifically those de-
liveries occurring during the study
period to womenwhose obstetric history
indicated a prior preterm birth (&37
weeks). We then evaluated the full
(paper) medical record for all women
who were identified as potentially
eligible for 17OHP-C through this initial
screening process.
We define index pregnancy as the
pregnancy that occurred between
January 1, 2012, and December 31, 2013,
and the pregnancy in which the woman
would have been eligible for 17OHP-C.
Our study cohort included women
whose index pregnancy was a singleton
gestation and who had a history of 1
singleton birth characterized by either
premature rupture of membranes or
spontaneous labor, occurring between
200/7 weeks and 36
6/7 weeks’ gestation.
We excluded women whose only
“qualifying” prior preterm birth was
indicated for maternal reasons (eg,
induction for preeclampsia), indicated
for fetal reasons (eg, fetal growth re-
striction with abnormal testing), or
associated with placental abruption. We
also excluded those whose index fetus
had a major structural anomaly. Finally,
we excluded from our primary analysis
those womenwhose prenatal care for the
index pregnancy was provided outside
North Carolina, because we had limited
access to those prenatal records. We
categorized cases in which there was
not enough available information to
determine the cause of the prior PTB as
“unknown.”
We examined the prenatal records
of the index pregnancy to determine
whether the patient had been offered
17OHP-C by evidence of documentation
of a provider discussing 17 P with the
patient. We also documented whether
the patient who had been offered 17 P
accepted or declined it. We extracted
information on the number of docu-
mented 17OHP-C injections received by
TABLE 1
Characteristics of 17OHP-Ceeligible women delivering at 2 North Carolina hospitals between January 1, 2012,
and December 31, 2013, who received ‡1 dose of 17OHP-C
Characteristic Total Covered Not covered P value
Age, y, n (%) .59
<24 130 22% 61 22% 69 22%
25e29 165 27% 75 26% 90 28%
30e34 191 32% 97 34% 94 29%
35 118 10% 51 18% 67 21%
Missing 23 12 11
Race/ethnicity, n (%) .03
White 314 52% 153 53% 161 50%
African American 114 19% 65 23% 49 15%
Other 20 3% 8 3% 12 4%
Hispanic 161 26% 63 22% 98 31%
Missing 18 7 11
Type of insurance, n (%) .48
Medicaid 352 56% 166 56% 186 57%
BC/BS 70 11% 32 11% 38 12%
Tricare 9 1% 5 2% 4 1%
Self-pay 101 16% 42 14% 59 18%
Other 92 15% 50 17% 42 13%
Missing 3 1 2
Gravidity, n (%) .38
<3 133 21% 66 22% 67 20%
3 or 4 286 46% 140 47% 146 44%
5 208 33% 90 30% 118 36%
Smoker, n (%) .83
Yes 121 20% 59 20% 62 20%
No 487 80% 232 80% 255 80%
EGA at first prenatal visit, weeks, n (%) .0001
<14 373 64% 204 72% 169 57%
14e20 117 20% 53 19% 64 22%
>20 92 16% 28 10% 64 22%
Missing 45 11 34
Prenatal visits, n (%) <.0001
<4 55 10% 18 6% 37 12%
4e10 259 44% 94 33% 165 55%
>10 268 46% 172 61% 96 32%
Missing 45 12 33
GA (weeks) at delivery of index pregnancy, mean (SD) 36.2 (4) 35.7 (4) 36.7 (4) .002
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TABLE 1
Characteristics of 17OHP-Ceeligible women delivering at 2 North Carolina hospitals between January 1, 2012,
and December 31, 2013, who received ‡1 dose of 17OHP-C (continued)
Characteristic Total Covered Not covered P value
Delivery type of index pregnancy, n (%) .01
Vaginal 441 72% 192 66% 249 77%
Cesarean 165 275 95 33% 70 22%
Assisted vaginal 10 2% 5 2% 5 2%
Missing 11 4 7
Place of delivery, n (%) .002
UNC 346 55% 144 49% 202 61%
Asheville 281 45% 152 51% 129 39%
County of residence .002
Urban 454 77% 238 82% 216 71%
Rural 139 23% 52 18% 87 29%
Missing 34 6 28
Any prior full-term births, n (%) <.0001
Yes 343 55% 131 44% 212 64%
No 284 45% 165 56% 119 36%
Number of prior full-term births, n (%) <.0001
0 284 45% 165 56% 119 36%
1 181 29% 78 26% 103 31%
2 105 17% 39 13% 66 20%
Number of prior preterm births, n (%) <.0001
1 477 765 206 70% 271 82%
2 106 17% 62 21% 44 13%
3 44 7% 28 10% 16 5%
Earliest GA of prior preterm births, n (%) <.0001
20 to <28 156 25% 117 40% 39 12%
28 to <32 57 9% 31 11% 26 8%
32 to <36 247 39% 121 41% 126 38%
36 167 27% 27 9% 140 42%
GA of most recent pregnancy before index pregnancy, n (%) <.0001
<20 89 14% 40 14% 49 15%
20e36 370 60% 207 70% 163 50%
37 163 26% 47 16% 116 35%
Missing 5 2
Columns may not add up to 100% due to rounding.
BC/BS, Blue Cross/Blue Shield; EGA, estimated gestational age; GA, gestational age; UNC, University of North Carolina Women’s Hospital.
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no documentation of whether or not a
woman had been offered the drug, but
there was evidence of her having receivedinjection(s), we assumed that it had been
offered. In some cases, women opted to
self-inject 17OHP-C at home, and in
those instances we assumed that shereceived it because inmost cases there was
no record of actual receipt in the chart.
We also extracted characteristics
potentially associated with non-receipt
FIGURE 2



















Critical path that must be negotiated by eligible gravidas in order to receive the 17OHP-C
intervention.
17P, 17OHP-C.
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ethnicity, gravidity, smoking status, and
type of insurance from each chart. Pre-
natal care data from the index preg-
nancy, including gestational age at the
start of prenatal care and number of
prenatal visits were collected. Finally, we
extracted detailed available information
on all prior pregnancies. We classified
each participant represented in the
sample as urban or rural according to her
county of residence using definitions
from the North Carolina Rural
Economic Development Center.20
Our primary outcome was “17OHP-C
failed coverage” defined as the proportion
of eligible women who had not received
1 dose of 17OHP-C. We also investi-
gated in additional analysis the outcome
of “not offered 17OHP-C,” which we
defined as the proportion of eligible
womenwho were not offered the drug by
their provider and “refused 17OHP-C,”
which we defined as the proportion of
women who refused the medication.
We fit logistic regression models to
estimate odds ratios (OR) for the asso-
ciation between selected correlates and 3
dichotomous outcomes: failed 17OHP-
C coverage, not offered 17OHP-C, and
refused 17OHP-C. We used a stepwise
regression approach with backward
elimination to select an adjusted model.
Main effects were retained in the model
if P values were <.2. We performed all
analyses with SAS version 9.4 software
(SAS Institute, Cary, NC).
We planned our sample size around a
balance between precision of the pri-
mary outcome estimate and projected
feasibility of the medical record review.
We anticipated that our time and re-
sources available would allow detailed
record extraction from approximately
600 charts. Assuming 50% 17OHP-C
coverage among participants, a sample
size of 600 eligible patients would pro-
vide 5% precision around this estimate
(ie, 17OHP-C coverage ¼ 0.50; 95%
confidence interval [CI], 0.45e0.55).We
estimated from prior experience that
approximately 5% of women in the
hospitals’ birth cohort would be eligible
for 17OHP-C,21 and selected our study
period to provide approximately 600
eligible patients. The study was approvedby the Institutional Review Boards of the
2 delivery hospitals.
Results
Between January 1, 2012, and December
31, 2013, a total of 14,725 women
delivered at the 2 hospitals
(Supplemental Table). Of those women,
1216 (8.2%) women had a prior preterm
birth. We excluded 577 women (47%)
for 17OHP-C noneligibility or unknown
eligibility after medical record review
(Figure 1). Once exclusions were
applied, we were left with 627 women
who were classified as 17OHP-C eligible.
Characteristics of women with a prior
spontaneous preterm birth are presented
in Table 1. Of the women who were
eligible to receive 17OHP-C, the major-
ity were of white ethnicity, and more
than half (56%) were covered by
Medicaid in the index pregnancy.
Approximately two-thirds (64%) pre-
sented to their first prenatal visit before
14 weeks’ gestation, and nearly half
(46%) had >10 prenatal visits. The
mean gestational age at delivery of the
index pregnancy was 36 weeks(interquartile range [IQR], 35e39).
Slightly more than half of the women
(55%) had 1 prior full-term birth,
whereas 25% reported 1 prior
extremely preterm birth (28 weeks).
Of the 627 women eligible to receive
17OHP-C for prematurity prevention,
only 296 (47%; 95% CI, 43e51%) met
our definition for coverage (ie, docu-
mented receipt of 1 dose of the drug).
17OHP-C coverage varied significantly
by hospital of delivery: at UNCWomen’s
Hospital, 144 of 346 of eligible women
(42%) were covered, compared to
Mission Hospital, where 152 of 281
eligible women (54%) were covered
(P ¼ .002).
We recreated and quantified the steps
along the critical path that each woman
with a prior PTB must negotiate to
benefit from 17OHP-C (Figure 2). Of
627 women who were eligible to receive
17OHP-C, 409 (65%) were offered it.
Of the 409 women who were offered
the drug, 301 (74%) accepted it, and of
those 301 who accepted, 296 (98%)
received 1 dose of the medication
(Figure 2).
TABLE 2
Correlates of overall failed 17OHP-C coverage and not having been offered 17OHP-C among eligible women delivering at 2 North Carolina hospitals
between January 1, 2012, and December 31, 2013
Not covered (vs covered) Not offered (vs offered) Not accepted (vs accepted)
OR 95% CI AOR 95% CI OR 95% CI AOR 95% CI OR 95% CI AOR 95% CI
Age, y
<25 1.00 Reference 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
25e29 1.06 0.67e1.68 1.42 0.87e2.32 1.55 0.74e3.24 0.71 0.38e1.32 0.54 0.24e1.22
30e34 0.86 0.55e1.34 1.11 0.68e1.80 1.00 0.49e2.01 0.73 0.41e1.32 0.51 0.23e1.12
35 1.16 0.70e1.92 1.97 1.17e3.33 1.95 0.89e4.27 0.60 0.29e1.25 0.24 0.08e0.72
Race/ethnicity
White 1.00 Ref 1.00 Ref 1.00 Ref
African American 0.72 0.47e1.10 0.84 0.52e1.34 0.58 0.31e1.10
Other 1.43 0.57e3.58 1.43 0.57e3.60 0.96 0.25e3.75
Hispanic 1.48 1.00e2.18 1.65 1.11e2.44 0.97 0.56e1.68
Type of insurance
BC/BS 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
Medicaid 0.94 0.56e1.58 0.99 0.48e2.06 1.10 0.63e1.91 0.76 0.39e1.48 0.94 0.38e2.31
Tricare 0.71 0.38e1.32 0.84 0.36e1.93 0.91 0.46e1.78 0.55 0.24e1.27 0.70 0.25e1.97
Self-pay 1.18 0.64e2.19 0.49 0.19e1.25 1.75 0.93e3.32 0.55 0.23e1.31 0.16 0.04e0.61
Other 0.67 0.17e2.72 — — 1.75 0.43e7.14 — — — —
Gravidity
<3 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
3e4 1.03 0.68e1.55 0.74 0.39e1.39 1.16 0.74e1.80 0.98 0.56e1.74
5 1.29 0.83e2.00 1.41 0.68e2.93 1.54 0.97e2.45 1.02 0.55e1.87
Smoker
Yes 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
No 1.05 0.70e1.56 1.63 0.89e3.00 1.42 0.92e2.20 2.17 1.11e4.26 0.76 0.45e1.29
EGA at first prenatal visit of index pregnancy
<14 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
14e20 1.46 0.96e2.21 1.10 0.59e2.05 1.41 0.91e2.20 0.93 0.48e1.81 1.23 0.69e2.19 0.69 0.32e1.51
>20 2.76 1.69e4.50 3.08 1.49e6.37 2.99 1.87e4.77 3.47 1.72e7.00 1.55 0.77e3.12 2.00 0.81e4.93
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TABLE 2
Correlates of overall failed 17OHP-C coverage and not having been offered 17OHP-C among eligible women delivering at 2 North Carolina hospitals
between January 1, 2012, and December 31, 2013 (continued)
Not covered (vs covered) Not offered (vs offered) Not accepted (vs accepted)
OR 95% CI AOR 95% CI OR 95% CI AOR 95% CI OR 95% CI AOR 95% CI
Prenatal visits
>10 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
4e10 3.14 2.20e4.49 3.85 2.35e6.31 3.02 2.05e4.44 3.19 1.86e5.48 2.38 1.47e3.87 3.11 1.67e5.81
<4 3.68 1.99e6.82 4.47 1.95,10.26 4.11 2.24e7.54 5.09 2.21,11.76 2.24 0.94e5.37 3.50 1.20e10.21
Place of delivery
Asheville 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
UNC 1.65 1.20e2.27 2.41 1.42e4.10 1.72 1.23e2.41 1.46 0.86e2.47 1.20 0.77e1.87 3.15 1.58,6.28
County of residence
Urban 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
Rural 1.84 1.25e2.72 2.32 1.57e3.43 1.80 0.97e3.35 1.07 0.60e1.92
Any prior full-term births
No 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
Yes 2.24 1.63e3.09 2.39 1.69e3.38 1.63 1.04e2.54 3.31 0.87e12.54
Number of full-term births
0 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
1 1.83 1.26e2.67 1.75 1.16e2.62 0.91 0.47e1.79 1.57 0.94e2.62 0.33 0.09e1.22
2 2.35 1.48e3.72 3.06 1.91e4.89 2.90 1.36e6.18 1.30 0.65e2.60 0.32 0.07e1.35
3 4.26 2.23e8.14 3.99 2.21e7.19 2.15 0.83e5.60 2.85 1.21e6.70 1.00 1.00e1.00
Number of prior preterm births
3 1.00 Ref 1.00 Ref 1.00 Ref
2 1.24 0.60e2.57 1.33 0.57e3.12 1.25 0.44e3.52
1 2.30 1.21e4.37 2.40 1.13e5.11 1.93 0.77e4.83
















































































































































































































































































































































































































































































































































































































































































































In multivariate regression, factors
associated with failed 17OHP-C
coverage included the following: delivery
at UNC Women’s Hospital compared to
Mission Hospital (adjusted odds ratio
[AOR], 2.4); presenting at >20 weeks’
gestation for the first prenatal visit
compared to <14 weeks’ gestation
(AOR, 3.1); attending <4 prenatal visits
(AOR, 4.5) versus >10, and attending
between 4 and 10 prenatal visits
compared to >10 (AOR, 3.9) (Table 2).
The covariate most strongly associ-
ated with failed 17OHP-C coverage was
the severity of a woman’s prior preterm
birth, in which we found evidence of
a doseeresponse relationship, with
increasingly later prior preterm births
associated with lower odds of 17OHP-C
coverage. Compared to women whose
earliest prior preterm birth was at 20 to
<28 weeks, there were successively
higher odds of failed 17OHP-C coverage
among women whose prior preterm
birth occurred at 32 to<36 weeks (AOR,
6.4) and >36 weeks (AOR, 38.3).
Women whose most recent pregnancy
before the index was>37 weeks also had
a higher odds of failed coverage when
compared to women whose most recent
pregnancy was <20 weeks (AOR 3.2)
(Table 2).
Among those women who were
“covered,” the median number of
17OHP-C injections was 9 (IQR, 4e15),
with 84 of 296 charts (28%) not having
complete information on the number of
doses. The median number of doses
among women delivering at UNC
Women’s Hospital was 11 (IQR, 4e15)
and in Ashville it was 7 (IQR, 3e16).
In additional analysis, we examined
covariates associated with not having
been offered 17OHP-C. In multivariable
analysis, we found factors associated
with the primary outcome to also be
associated with this secondary outcome,
with very similar strengths of associa-
tion. Two exceptions included non-
smokers, who had lower odds of being
offered 17OHP-C than did smokers
(AOR, 2.2) and women living in rural
areas, who trended toward higher odds
of not being offered the drug than did
women living in urban areas (AOR, 1.8)
(Table 2). Finally, we examined
covariates associated with refusing
17OHP-C. In multivariable analysis, we
found that women who delivered at
UNC Women’s Hospital were 3.2 times
as likely to refuse 17OHP-C as women
delivering in Asheville.Womenwere also
much more likely to refuse 17OHP-C if
their prior preterm birth was a late pre-
term birth and if the most recent preg-
nancy prior to the index pregnancy was a
term delivery.
Comment
In this retrospective cohort study con-
ducted at 2 large regional perinatal cen-
ters in North Carolina, we found
unacceptably low coverage of 17OHP-C
among eligible women. Only 47% of
eligible women in our cohort had docu-
mentation of a single dose of the drug,
which was lower than we had expected.
This finding confirms our hypothesis that
many women at risk for recurrent pre-
term birth are not accessing 17OHP-C,
despite its almost universal availability in
our state through both private and public
payers, and through a donation program
sponsored by the manufacturer.
Our primary failed coverage outcome
was strongly associated with key clinical
factors, including later presentation to
prenatal care, fewer prenatal visits, and
severity of the prior “qualifying” preterm
birth. Failed coverage also varied be-
tween the delivery hospitals, which,
because of their geographic separation,
serve largely distinct antenatal practices
at which 17OHP-C would be prescribed
and administered.
Our study shows not only that a gap in
17OHP-C coverage exists, but that there
are problems with failure of providers to
offer the treatment as well as failure of
patients to accept the intervention. A
previous survey among obstetricians on
the use of 17OHP-C reported that only
59% of the physicians surveyed pre-
scribed 17OHP-C to their eligible pa-
tients.22 Logistical reasons and financial
reasons were cited as the 2 most com-
mon reasons for not prescribing the
drug. A secondary aim of our study was
to develop methods that might be used
for ongoing monitoring and quality
assurance. We found that identifying a
woman as eligible for 17OHP-C throughchart review is not always as straight-
forward as one might assume, and we
hypothesize that prenatal providers are
faced with similar ambiguous clinical
situations in the real world. The ACOG/
SMFM guidelines advise that “a woman
with a singleton gestation and a prior
spontaneous preterm singleton birth
should be offered progesterone supple-
mentation starting at 16e24 weeks of
gestation to reduce the risk of recurrent
spontaneous preterm birth,” leaving
room for interpretation in several situa-
tions.17,18 For instance, the guidelines
are silent on whether 17OHP-C should
be prescribed when (1) the prior preterm
birth was associated with placental
abruption, (2) the prior preterm birth
was a twin gestation, (3) the index
pregnancy is a twin gestation, (4) the
prior preterm birth occurred before 20
weeks’ gestation, and (5) the clinical
circumstances of the prior preterm birth
are unclear/ambiguous. It likely that this
lack of clarity is contributing to failed
coverage. Iams and other experts have
argued for expanded coverage of 17OHP-
C to include womenwith a prior preterm
birth as early as 16 weeks, when feasible,
as well as offering it to women when the
etiology is unclear.23,24 Although we
decided to define eligibility based on
ACOG and SMFM guidelines, it is not
unreasonable to advocate for revisions to
this advice. Based on our data, we think
that expanding potential indications for
offering 17OHP-C may help with
coverage.
North Carolina was an early adopter
of 17OHP-C, with Medicaid paying for
the drug as early as 2008.16 Our study is
among 1 of the first reports on the actual
implementation of 17OHP-C among
eligible women and is, to our knowledge,
the only one that actually quantifies
17OHP-C coverage, 17OHP-C offered,
and 17OHP-C received in a representa-
tive sample. Orsulak and colleagues have
previously reported that the only 7.4% of
eligible women covered by Medicaid
received 17OHP-C in Louisiana in
2010.25 We chose a retrospective cohort
design because we wanted to understand
the pragmatic issues around measuring
17OHP-C coverage before launching a
larger prospective effort.Interestingly, women who received
17OHP-C delivered at an earlier gesta-
tional age than those women who did
not receive 17OHP-C. These women
were more likely to have had an earlier
prior preterm birth, which we think ex-
plains why they delivered at an earlier
gestational age. It is possible that women
who received 17OHP-C, although many
still delivered preterm, delivered at later
gestational ages than they would have
had they not received 17OHP-C. More
studies are needed to determine differ-
ences between women who respond to
17OHP-C and those who do not.26 In
addition, our hypothesis for the differ-
ences between coverage at Mission
Hospital and UNC is that Mission has a
more defined outreach area compared to
UNC and the Mission catchment area
includes a single maternalefetal medi-
cine group giving a consistent message
on 17OHP-C.
Our study suffers from the usual
challenges of a retrospective cohort
analysis, including potential ascertain-
ment bias and misclassification bias.27
We were limited by the available infor-
mation in the charts and the nonsys-
tematic way in which information is
captured. It was not uncommon to
encounter a medical record in which
17OHP-C had been administered but in
which there was no documentation that
the patient was offered it. It is therefore
possible that ascertainment error has
been introduced at the individual points
of attrition along the 17OHP-C cascade
(offered, accepted). However, we are
confident that the actual administration
of drug is being accurately documented
when it is administered in the clinic
setting. When the 17OHP-C was
administered at home, we were not able
to quantify the number of injections that
the patient actually received because it
was not well documented in the chart.
We were particularly limited in our
ability to discern the number of doses
of 17OHP-C that a patient received,
because repeat injection data are not well
captured in the records. The few patients
who self-administer 17OHP-C do not
typically have all doses recorded in
the medical record. Patients covered by
North Carolina Medicaid for Pregnant
Women must have 17OHP-C adminis-
tered at the clinic. Although this may 
help in capturing data about doses 
administered, it may be another barrier 
to receipt. A study that includes focus 
groups with pregnancy medical home 
care coordinators and with women 
eligible for 17OHP-C was recently con-
ducted in North Carolina to explore 
individual patient barriers to uptake of 
the intervention. Finally, our study was 
conducted only among women who 
delivered at 2 large medical centers in 
North Carolina and may not be repre-
sentative of all women across the state of 
North Carolina.
This study confirmed our anecdotal 
experience of significant gaps in 17OHP-
C coverage, but also taught us that retro-
spective review of paper records is labor 
intensive and is not a feasible solution to 
monitor population coverage. We believe 
that developing a better methodology for 
measuring 17OHP-C coverage, such as 
linking electronic birth records with 
claims data, will be necessary for success, 
and should be a key research priority. We 
also found that reasons for failed coverage 
likely are due to a multitude of different 
reasons, and that to have a meaningful 
population increase in 17OHP-C, the 
solutions will need to be individualized 
for patients, clinics, and communities. 
Improving coverage of 17OHP-C will not 
only result in improved patient care and 
birth outcomes but also tremendous 
savings to the health care system.28 
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SUPPLEMENTAL TABLE
Characteristics of eligible women delivering at the University of North




Age, years, (n%) <0.0001
<24 46 14.2 84 29.9
25-29 96 29.7 69 24.6
30-34 109 33.8 82 29.2
35+ 72 22.3 46 16.4
Missing 23 0
Race/Ethnicity, n (%) <0.0001
Caucasian 105 31.5 209 75.7
African American 82 24.6 32 11.6
Other 11 3.3 9 3.3
Hispanic 135 40.5 26 9.4
Missing 13 5
Type of insurance, n (%) <0.0001
Medicaid 158 46.1 194 69.0
BC/BS 10.2 35 12.5
Tricare 8 2.3 1 0.4
Self-pay 90 26.2 11 3.9
Other 52 15.2 40 14.2
Missing 3 35 0
Gravidity, mean (SD) n (%) 0.02
<3 70 20.2 63 22.4
3-4 145 41.9 141 50.2
 5 131 37.9 77 27.4
Smoker, n (%) <0.0001
Yes 37 11.3 84 30.0
No 291 88.7 196 70.0
Missing 18 1
EGA at 1st prenatal visit, n (%)
<14 <0.0001
14-20 189 62.6 184 65.7
>20 79 26.2 38 13.6
Missing 34 11.3 58 20.7
Prenatal visits, n (%) 0.002
<4 17 5.7 38 13.5
4-10 148 49.2 111 39.5
>10 136 45.2 132 47.0
Missing 45 0
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SUPPLEMENTAL TABLE
Characteristics of eligible women delivering at the University of North




GA at delivery of index pregnancy,
mean (SD)
36.5 (4.0) 35.9 (4.5) 0.06
Delivery Type of index pregnancy,
n (%)
0.85
Vaginal 237 70.8 204 72.6
Cesarean delivery 92 27.5 73 26.0
Assisted vaginal delivery 6 1.8 4 1.4
Missing 11 0
County of residence <0.0001
Urban 211 67.0 243 87.4
Rural 104 33.0 35 12.6
Missing 31 3
Any prior full term births, n (%) 0.08
Yes 200 57.8 143 50.9
No 146 42.2 138 49.1
Number of prior full term births,
n (%)
0.02
0 146 42.2 138 49.1
1 96 27.8 85 30.3
2 63 18.2 42 15.0
Number of prior preterm births,
n (%)
0.02
1 276 79.8 201 71.5
2 53 15.3 53 18.9
3+ 17 4.9 27 9.6
Earliest GA of prior preterm births,
n (%)
0.003
20-<28 101 29.2 55 19.6 101
28-<32 38 11.0 19 6.8
32-36 109 31.5 138 49.1
36þ 98 28.3 69 24.6 98
GA of most recent pregnancy prior to
the index pregnancy, n (%)
0.55
<20 45 13.2 44 15.7 45
20-36 202 59.2 168 59.8 202
37þ 94 27.6 69 24.6 94
Missing 5 0 5
EGA, estimated gestational age.
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